Skip to Content
Cancer Therapy Evaluation Program (CTEP)
Last Updated: 01/08/15

Helen X. Chen, MD

Associate Chief and Medical Officer

Dr. Helen Chen joined the Cancer Therapy Evaluation Program (CTEP) of National Cancer Institute (NCI) in 2000. She currently serves as Associate Chief of the Investigational Drug Branch (IDB) Section III, which focuses on the clinical development of antibody-based therapeutics, active immunotherapies, MAPK and RTK inhibitors as well as antiangiogenic agents. She has also been closely involved in NCI’s efforts on novel agent combinations and is member of the NCI Experimental Therapeutics Committee.

Dr. Chen graduated from the Shanghai First Medical College of the Fudan University in China. She is board-certified in Medical Oncology after completing the Fellowship Training at Georgetown University Medical Center, Washington D.C. Dr. Chen also serves on external scientific committees including the International Symposium of Anti-angiogenic Therapies and Immunotherapy and the FDA-ASCO-AACR-sponsored Accelerating Anticancer Agent Development and Validation Workshop. She has presented at national and international meetings on strategies of combining novel and targeted agents, early drug development as well as antibody-based therapeutics and antiangiogenic therapies. She is the first or coauthor of over 50 original and review papers in peer-reviewed journals including Journal of Clinical Oncology, Nature Reviews, and New England Journal of Medicine.

Contact Information:
National Cancer Institute
9609 Medical Center Dr., MSC 9739
For USPS: Bethesda, MD 20892-9739
For Express and Courier: Rockville, MD 20850
Phone: 240-276-6565
Fax: 240-276-7894
E-mail: Helen.chen@nih.gov

About the Branch Chief

James Zwiebel, MD James Zwiebel received the MD degree from the Mount Sinai School of Medicine, where he also completed his residency training in internal medicine. Following a clinical fellowship in hematology and oncology at the George Washington University Medical Center and research fellowships at both the National Cancer Institute and the National Heart Lung and Blood Institute, he continued his laboratory work on cancer gene therapy as a member of the faculty at Lombardi Cancer Center of the Georgetown University Medical Center, where he also practiced hematology and oncology. More…